¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"international insulin unit"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin resistance
    Àν¶¸°ÀúÇ×, Àν¶¸°³»¼º
  • insulin sensitivity index
    Àν¶¸°¹Î°¨Áö¼ö
  • insulin shock
    Àν¶¸°¼îÅ©
  • insulin-dependent
    Àν¶¸°ÀÇÁ¸-
  • insulin-dependent diabetes
    Àν¶¸°ÀÇÁ¸´ç´¢º´
  • insulin-induced hypoglycemia
    Àν¶¸°À¯µµÀúÇ÷´ç(Áõ)
  • insulin-like activity
    Àν¶¸°À¯»çȰ¼ºµµ
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • insulin-resistant diabetes
    Àν¶¸°ÀúÇ×´ç´¢º´
  • insulin-to-glucose ratio
    Àν¶¸°´ëÆ÷µµ´çºñ
  • intermediate-acting insulin
    Áß°£ÀÛ¿ëÀν¶¸°
  • long acting insulin
    Áö¼ÓÀÛ¿ëÀν¶¸°
  • non-insulin-dependent diabetes
    ºñÀν¶¸°ÀÇÁ¸´ç´¢º´
  • NPH insulin
    NPHÀν¶¸°
  • purified insulin
    ¼ø¼öÀν¶¸°, Á¤Á¦Àν¶¸°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin receptor
    Àν¶¸°¼ö¿ëü
  • insulin resistance
    Àν¶¸°ÀúÇ×
  • insulin shock
    Àν¶¸°¼îÅ©
  • insulin sensitivity index
    Àν¶¸°°¨¼ºÁö¼ö
  • insulin-to-glucose ratio
    Àν¶¸°Æ÷µµ´çºñÀ²
  • long acting insulin
    Áö¼ÓÀν¶¸°
  • purified insulin
    ¼ø¼öÀν¶¸°
  • short acting insulin
    ´Ü±âÀÛ¿ëÀν¶¸°
  • suppressive insulin
    ¾ïÁ¦Àν¶¸°
  • aesthetic unit
    ¹Ì¿ë´ÜÀ§
  • angstrom unit
    ¿Ë½ºÆ®·Ò´ÜÀ§
  • antitoxin unit
    Ç×µ¶¼Ò°¡
  • atomic mass unit
    ¿øÀÚÁú·®´ÜÀ§
  • burst-forming unit
    ´ëÁý¶ôÇü¼º´ÜÀ§
  • coding unit
    ºÎȣ󸮴ÜÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anti-insulin
    Ç×Àν¶¸°.
  • arginine-insulin test
    ¾Æ¸£±â´Ñ-Àν¶¸°½ÃÇè
  • globin insulin
    ±Û·ÎºóÀν¶¸°.
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • high purified insulin
    °í¼ø¼öÀν¶¸°.
  • immunoreactive insulin =IRI
    ¸é¿ª¹ÝÀÀ¼º(¡­Úãëëàõ) Àν¶¸°.
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
  • insulin secreting islet cell tumor
    Àν¶¸° ºÐºñ¼º µµ¼¼Æ÷Á¾¾ç.
  • insulin sensitivity
    Àν¶¸°°¨(¼ö)¼º.
  • insulin sensitivity index
    Àν¶¸°°¨¼ºÁö¼ö.
  • insulin sensitivity test
    Àν¶¸°°¨¼º½ÃÇè.
  • insulin shock
    Àν¶¸°¼ï.
  • insulin shock therapy
    Àν¶¸°¼ï¿ä¹ý.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • globin insulin
    ±Û·ÎºóÀν¶¸°.
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • high purified insulin
    °í¼ø¼öÀν¶¸°.
  • immunoreactive insulin =IRI
    ¸é¿ª¹ÝÀÀ¼º(¡­Úãëëàõ) Àν¶¸°.
  • insulin
  • insulin antagonist
    Àν¶¸°±æÇ×ü.
  • insulin antagonist
    Àν¶¸°±æÇ×Á¦.
  • insulin antiserum
    Ç×Àν¶¸°Ç÷û.
  • insulin coma therapy
    Àν¶¸° È¥¼ö Ä¡·á
  • insulin convulsive therapy combined
    Àν¶¸°°æ·Ãº´ÇÕÄ¡·á<¿ä¹ý>
  • insulin convulsive therapy combined
    Àν¶¸°°æ·Ãº´ÇÕÄ¡·á<¿ä¹ý>.
  • insulin deficiency diabetes
    Àν¶¸°°áÇ̼º ´ç´¢º´.
  • insulin dependence
    Àν¶¸°ÀÇÁ¸¼º.
  • insulin dependent diabetes mellitus =IDDM
    Àν¶¸°ÀÇÁ¸¼º ´ç´¢º´.
  • insulin edema
    Àν¶¸°ºÎÁ¾(¡­Ý©ðþ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • protamine zinc insulin
    ÇÁ·ÎŸ¹Î ¾Æ¿¬(䬿ç) Àν¶¸°
  • suppressible insulin-like activity
    ¾ï¾Ð °¡´É(åääâʦÒö) Àν¶¸°À¯»çȰ¼º(×¾ÞÄüÀàõ)
  • absorbance unit
    Èí±¤´ÜÀ§ (ýåÎÃÓ¤êÈ)
  • angstrom unit
    ¿Ë±×½ºÆ®·Ò ´ÜÀ§(Ó¤êÈ)
  • atomic weight unit
    ¿øÀÚ(ê«í­)¹«°Ô ´ÜÀ§(Ó¤êÈ)
  • atomoc mass unit
    ¿øÀÚ Áú·®´ÜÀ§ (ê«í­òõÕáÓ¤êÈ)
  • chlorophyll unit
    ¿±·Ï¼Ò ´ÜÀ§(ç¨ÖàáÈÓ¤êÈ)
  • C'H50 unit
    C'H50 ´ÜÀ§(Ó¤êÈ)
  • crossover unit
    ±³Â÷´ÜÀ§(Îßó©Ó¤êÈ)
  • C1 unit
    "C1 ´ÜÀ§(Ó¤êÈ) (ÔÒ) active one-carbon unit,"
  • entropy unit
    ¿£Æ®·ÎÇÇ ´ÜÀ§(Ó¤êÈ)
  • enzyme unit
    È¿¼Ò´ÜÀ§ (ý£áÈÓ¤êÈ)
  • Fick unit
    ÇÈ ´ÜÀ§ (Ó¤êÈ)
  • kat F unit
    īŻ F ´ÜÀ§(Ó¤êÈ)
  • map unit
    Áöµµ´ÜÀ§(ò¢ÓñÓ¤êÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AU according to custom [Lat. ad usum]; allergenic unit; ngstrom unit; antitoxin unit; arbitrary unit; A...
CCU cardiac care unit; Cherry-Crandall unit; coronary care unit; critical care unit
MU megaunit; mescaline unit; methyluric [acid]; Montevideo unit; motion unsharpness; motor unit; mouse ...
PCU pain control unit; primary care unit; patient care unit; pulmonary care unit
RU radioulnar; rat unit; reading unit; residual urine; resin uptake; resistance unit; retrograde urogra...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IASP International Association for the Study of Pain
IAEA International Atomic Energy Agency
IBMTR International Bone Marrow Transplant Registry
ICDDR, B International Centre for Diarrhoeal Disease Research, Bangladesh
ICNP International Classification for Nursing Practice
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigen unit
    Ç׿ø ´ÜÀ§
  • antitoxic unit
    Ç×µ¶¼Ò ´ÜÀ§, Ç×µ¶¼Ò¼º ´ÜÀ§
  • clinical unit
    ÀÓ»ó ´ÜÀ§
  • colony-building unit
    ±ºÃ¼ Çü¼º ´ÜÀ§
  • ecological unit
    »ýÅ ´ÜÀ§
  • electrostatic unit
    Á¤Àü ´ÜÀ§
  • hemorrhagin unit
    Çì¸ð¶óÁø ´ÜÀ§
    ºÎÈ­ 3ÀϰÀÇ °è¹èÀÇ ¸ð¼¼Ç÷°ü¸Á¿¡ ÃâÇ÷À» ÀÏÀ¸Å³ ¼ö ÀÖ´Â »çµ¶ÀÇ ¾ç.
  • hypothetical unit
    °¡Á¤ ´ÜÀ§
    ¼¼Æ÷ ¿øÇüÁúÀ» Çü¼ºÇÏ´Â ±ØÈ÷ ¹Ì¼¼ÇÑ ºÐÀÚÀÇ ÁýÇÕÀ¸·Î, ¼ºÀå, »ý½Ä µîÀÇ ±âº» ´ÜÀ§ÀÌ´Ù.
  • kinetic unit
    ¼Óµ¿¼º ´ÜÀ§
  • lung unit
    Æó ´ÜÀ§
    ÆóÀÇ ¼¼±â°üÁö¿¡¼­ ¿øÀ§¿¡ Àִ ȣÈíÁ¶Á÷ÀÇ ÃÑĪÀ¸·Î, ÁÖ·Î ÆóÆ÷¿Í ±× ºÎ¼Ó Á¶Á÷.
  • map unit
    ¿°»öü Áöµµ ´ÜÀ§
    µ¿ÀǾî=ma
  • maximum security unit
    ÃÖ´ë ¾ÈÀü º´µ¿
  • mouse unit
    ¸¶¿ì½º ´ÜÀ§
  • neuromuscular unit
    ½Å°æ±Ù ´ÜÀ§
  • operational unit
    ÀÛ¿ë ´ÜÀ§
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
international system of units A system of physical units in which the fundamental quantities are length, time, mass, electric current, temperature, luminous intensity, and amount of substance, and the corresponding units are the meter, second, kilogram, ampere, kelvin, candela, and mole. The system has been given official status and recommended for universal use by the general conference on weights and measures.
(12 Dec 1998)
Leiter International Performance Scale A nonverbal (performance) test for measuring intelligence which contains norms for each age between 2 and 18; originally developed as a method of assessing the comparative intellectual abilities of Caucasian, Chinese, and Japanese children, but now occasionally used for assessing slow learners and those who are blind, deaf, or verbally handicapped.
(05 Mar 2000)
amorphous insulin zinc suspension Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
anti-insulin A factor, usually an antibody, which antagonises the action of insulin.
(05 Mar 2000)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
biphasic insulin <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin.
(09 Oct 1997)
receptors, insulin Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation.
(12 Dec 1998)
receptors, insulin-like-growth factor I Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity.
(12 Dec 1998)
receptors, insulin-like-growth-factor II Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity.
(12 Dec 1998)
regular insulin A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours.
Synonym: globin insulin.
(05 Mar 2000)
regular insulin injection A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma.
Synonym: regular insulin injection.
(05 Mar 2000)
globin insulin A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours.
Synonym: globin insulin.
(05 Mar 2000)
globin zinc insulin A sterile solution of insulin modified by the addition of zinc chloride and globin; it contains 40 or 80 units per ml; duration of action is about 18 hours.
Human insulin, a protein that has the normal structure of insulin produced by the human pancreas, prepared by recombinant DNA techniques and by semisynthetic processes.
Immunoreactive insulin (IRI), that portion of insulin in blood measured by immunochemical methods for the hormone; presumed to represent the free (unbound) and biologically active fraction of total blood insulin.
Isophane insulin, a modified form of insulin composed of insulin, protamine, and zinc; an intermediately acting preparation used for the treatment of diabetes mellitus.
Synonym: NPH insulin.
(05 Mar 2000)
crystalline insulin zinc suspension A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours.
Synonym: crystalline insulin zinc suspension.
(05 Mar 2000)
prompt insulin zinc suspension Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • message unit
    (ÀüÈ­ ¿ä±Ý °è»êÀÇ) ÅëÈ­´ÜÀ§;ÅëÈ­µµ
  • microprocessing unit
    ÃʼÒÇü ¿¬»ê ó¸® ÀåÄ¡
  • mobile unit
    ÅÚ·¹ºñÀü Ä«¸Þ¶ó Á¶Á¤ ¸ð´ÏÅÍ ÀåÄ¡;¼Û½Å ÀåÄ¡¸¦ ºñÄ¡ÇÑ ´ëÇü Æ®·°
  • neighborhood unit
    (¿µ)±Ù¸° ÁÖÅÃÁö±¸(Àα¸ 1¸¸¸í Á¤µµÀÇ µµ½Ã °èȹ´ÜÀ§)
  • panzer unit
    ±â°èÈ­ ºÎ´ë;±â°© »ç´Ü
  • peripheral device(unit)
    ÁÖº¯ÀåÄ¡
  • power unit
    ³»¿¬ ±â°ü
  • price per unit
    (»óǰÀÇ) ÇÒÀÎ ÀüÀÇ ´Ü°¡;(īŻ·Î±× µî¿¡ ³ª¿Í ÀÖ´Â) ÆÇ¸Å Èñ¸Á °¡°Ý
  • relay mobile (unit)
    (¹æ¼Û¿ë)Áß°èÂ÷
  • sink unit
    ºÎ¾ý ¼³ºñ(¼öä,ÂùÀå,Á¶¸®´ë)
  • synchro unit
    µ¿±â Àüµ¿±âÀÇ ÀÏÁ¾
  • tail unit
    ¹ÌÀÍ
  • unit
    ÇѰ³;(±¸¼º)´ÜÀ§;ÇÑ»ç¶÷
  • unit character
    (MendelÀÇ ¹ýÄ¢)´ÜÀÏ ÇüÁú
  • unit cost
    ´ÜÀ§ ¿ø°¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á